Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT)
In the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benefits of ICT, its use is complicated by the potential risk of i...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/crom/5582848 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1841542602344628224 |
---|---|
author | Saivaroon Gajagowni Emily Wang Jianbo Wang Matthew T. Campbell Bilal A. Siddiqui |
author_facet | Saivaroon Gajagowni Emily Wang Jianbo Wang Matthew T. Campbell Bilal A. Siddiqui |
author_sort | Saivaroon Gajagowni |
collection | DOAJ |
description | In the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benefits of ICT, its use is complicated by the potential risk of immune-related adverse events (irAEs). One rare but potentially life-threatening irAE is hemophagocytic lymphohistiocytosis (HLH). HLH is a systemic inflammatory disorder resulting in multiorgan failure. The diagnosis of HLH is a challenge due to nonspecific symptoms and overlap with other systemic conditions, which can lead to delays in receiving appropriate treatment and potentially poor patient outcomes. This case illustrates the management of HLH caused by nivolumab plus ipilimumab combination therapy through the use of corticosteroids and tocilizumab in a patient with metastatic clear cell renal cell carcinoma. |
format | Article |
id | doaj-art-0de79a2bb5fc44af919b63b843305706 |
institution | Kabale University |
issn | 2090-6714 |
language | English |
publishDate | 2025-01-01 |
publisher | Wiley |
record_format | Article |
series | Case Reports in Oncological Medicine |
spelling | doaj-art-0de79a2bb5fc44af919b63b8433057062025-01-14T00:00:04ZengWileyCase Reports in Oncological Medicine2090-67142025-01-01202510.1155/crom/5582848Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT)Saivaroon Gajagowni0Emily Wang1Jianbo Wang2Matthew T. Campbell3Bilal A. Siddiqui4Division of Internal MedicinePharmacy Clinical ProgramsDepartment of Genitourinary Medical OncologyDepartment of Genitourinary Medical OncologyDepartment of Genitourinary Medical OncologyIn the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benefits of ICT, its use is complicated by the potential risk of immune-related adverse events (irAEs). One rare but potentially life-threatening irAE is hemophagocytic lymphohistiocytosis (HLH). HLH is a systemic inflammatory disorder resulting in multiorgan failure. The diagnosis of HLH is a challenge due to nonspecific symptoms and overlap with other systemic conditions, which can lead to delays in receiving appropriate treatment and potentially poor patient outcomes. This case illustrates the management of HLH caused by nivolumab plus ipilimumab combination therapy through the use of corticosteroids and tocilizumab in a patient with metastatic clear cell renal cell carcinoma.http://dx.doi.org/10.1155/crom/5582848 |
spellingShingle | Saivaroon Gajagowni Emily Wang Jianbo Wang Matthew T. Campbell Bilal A. Siddiqui Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) Case Reports in Oncological Medicine |
title | Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) |
title_full | Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) |
title_fullStr | Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) |
title_full_unstemmed | Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) |
title_short | Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) |
title_sort | hemophagocytic lymphohistiocytosis hlh following immune checkpoint therapy ict |
url | http://dx.doi.org/10.1155/crom/5582848 |
work_keys_str_mv | AT saivaroongajagowni hemophagocyticlymphohistiocytosishlhfollowingimmunecheckpointtherapyict AT emilywang hemophagocyticlymphohistiocytosishlhfollowingimmunecheckpointtherapyict AT jianbowang hemophagocyticlymphohistiocytosishlhfollowingimmunecheckpointtherapyict AT matthewtcampbell hemophagocyticlymphohistiocytosishlhfollowingimmunecheckpointtherapyict AT bilalasiddiqui hemophagocyticlymphohistiocytosishlhfollowingimmunecheckpointtherapyict |